Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant stereotactic radiotherapy plus temozolomide after surgery for newly diagnosed supratentorial glioblastoma
ChiCTR2500100635Phase 2Not yet recruiting
- Sponsor
- First Hospital of China Medical University
- Start
- Apr 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temozolomide in glioblastoma (GBM), sponsored by First Hospital of China Medical University. Primary endpoint: Progression-free survival. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
temozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on ChiCTR2500100635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500100635.